An introduction to Zealand
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a pipeline of proprietary product candidates which primarily target specialty disease areas with significant unmet medical needs and a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn.
The company’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed globally outside the United States as Lyxumia® and approved in the U.S. as AdlyxinTM. A fixed-ratio combination of lixisenatide with insulin glargine (Lantus®), referred to as iGlarLixi, is under regulatory review in the U.S. and in Europe.
Zealand’s proprietary pipeline of product candidates includes: Dasiglucagon (proposed International Nonproprietary Name (pINN)) single-dose rescue treatment for acute, severe hypoglycemia (Phase II); ZP1848 for short bowel syndrome (Phase II); Dasiglucagon* (ZP4207) multiple-dose intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management (in preparation for Phase II); and other earlier stage clinical and preclinical peptide therapeutics.
The company is based in Copenhagen (Glostrup), Denmark.
Zealand has ~110 employees of which 80% work in research and development.
Follow us on Twitter: @ZealandPharma
Follow us on LinkedIn